Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1413-1424

  Nabholtz, J M ^a   Senn, H J ^a   Bezwoda, W R ^a   Melnychuk, D ^a   Deschenes L ^a   Douma, J ^a   Vandenberg, T A ^a   Rapoport, B ^a   Rosso, R ^a   Trillet Lenoir, V ^a   Drbal, J ^a   Molino, A ^a   Nortier, J W R ^a   Richel, D J ^a   Nagykalnai, T ^a   Siedlecki, P ^a   Wilking, N ^a   Genot, J Y ^a   Hupperets, P S G J ^a   Pannuti, F ^a   Skarlos, D ^a   Tomiak, E M ^a   Murawsky, M ^a   Alakl, M ^a   Riva, A ^a   Aapro, M ^a   more..

^a Greece

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; MITOMYCIN; VINBLASTINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032949449     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1413     Document Type: Article

References (26)

1. Flamm Honig S: Treatment of metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1996, pp 669-734
2. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 38:13-20, 1976
3. Sedlacek SM: Salvage therapy for metastatic disease. Semin Oncol 17:45-49, 1990 (suppl 7)
4. Garewal HS: Mitomycin C in the chemotherapy of advanced breast cancer. Semin Oncol 15:74-79, 1988 (suppl 4)
5. Buzdar AU: Chemotherapeutic approaches to advanced breast cancer. Semin Oncol 15:65-70, 1988 (suppl 4)
6. Radford JA, Knight RK, Rubens RD: Mitomycin C and vinblastine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 21:1475-1477, 1985
7. Konits PH, Aisner J, van Echo DA, et al: Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48:1295-1298, 1981
8. Garewal HS, Brooks RJ, Jones SE, et al: Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. J Clin Oncol 1:772-775, 1983
9. Navarro M, Bellmunt J, Balañá C, et al: Mitomycin-C and vinblastine in advanced breast cancer. Oncology 46:137-142, 1989
10. Denefrio JM, East DR, Troner MB, et al: Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. Cancer Treat Rep 62:2113-2115, 1978
11. Rosner D, Nemoto T: Mitomycin C and Velban® as fourth-line chemotherapy in metastatic breast cancer: A pilot trial. Proc Am Soc Clin Oncol 6:51, 1987 (abstr 196)
12. van Oosterom AT: Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer. Semin Oncol 22:22-28, 1995 (suppl 13)
13. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
14. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
15. Collett D (ed): Modelling Survival Data in Medical Research. London, United Kingdom, Chapman and Hall, 1994
16. Fumoleau P, Seidman AD, Trudeau ME, et al: Docetaxel: A new active agent in the therapy of metastatic breast cancer. Exp Opin Invest Drugs 6:1853-1865, 1997
17. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
18. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center Trial. J Clin Oncol 13:2056-2065, 1995
19. Vermorken JB, ten Bokkel Huinink WW, Mandjes IAM, et al: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol 22:16-22, 1995 (suppl 8)
20. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
21. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
22. Dieras V, Marty M, Tubiana N, et al: Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22:33-39, 1995 (suppl 8)
23. Gamucci T, Piccart M, Brüning P, et al: Single agent Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17:111a, 1998 (abstr 428)
24. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)
25. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
26. Riva A, Fumoleau P, Roché H, et al: Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere®. Proc Am Soc Clin Oncol 16:188a, 1997 (abstr 660)